Our Pricing

Semaglutide Injections UK - Private Prescription Route

Published on: June 03, 2026

Accessing semaglutide injections UK private prescription services has become increasingly straightforward for patients seeking clinically proven weight loss treatment. At Cured Pharmacy, we offer Wegovy (semaglutide) from £79.00 with transparent upfront pricing, UK-registered prescribers, and discreet next-day delivery across the United Kingdom.

How Semaglutide Works for Weight Loss

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics a naturally occurring hormone in your body. When administered as a weekly subcutaneous injection, it works through three distinct mechanisms: slowing gastric emptying to prolong satiety, reducing appetite signals in the brain, and improving insulin secretion to stabilise blood glucose levels [1].

The STEP clinical trial programme demonstrated that adults using semaglutide 2.4mg weekly achieved an average 14.9% body weight reduction over 68 weeks, compared to 2.4% with placebo [1]. Participants also reported improvements in cardiometabolic risk factors including blood pressure, lipid profiles, and inflammatory markers [2].

Unlike older weight loss medications that work through single pathways, semaglutide's multi-mechanism approach addresses the complex hormonal dysregulation underlying obesity. This explains why clinical outcomes have consistently exceeded earlier pharmacological interventions licensed by the MHRA for weight management.

Private Prescription vs NHS Access for Semaglutide

The NHS currently offers semaglutide injections through specialist weight management services, but eligibility criteria are restrictive and waiting times can extend beyond 12 months in many Clinical Commissioning Groups. NICE guidelines recommend GLP-1 treatments only for patients with BMI ≥35 kg/m² (or ≥32.5 kg/m² for certain ethnic groups) plus at least one weight-related comorbidity, and only after structured lifestyle programmes have been attempted [3].

Private prescription routes provide broader access for patients who meet clinical safety criteria but fall outside NHS eligibility thresholds. At Cured Pharmacy, our UK-registered prescribers assess suitability based on your individual medical history, current BMI, previous weight loss attempts, and contraindications — typically completing consultations within 24 hours of submission.

Private treatment also eliminates the administrative delays inherent in NHS referral pathways. Once your prescription is approved, medication is dispensed from our GPhC-registered pharmacy (9012511) and dispatched the same working day in discreet packaging, allowing you to begin treatment without the months-long wait often experienced through public healthcare channels.

Who Can Access Private Semaglutide Prescriptions

UK prescribers typically consider private semaglutide prescriptions for adults with BMI ≥30 kg/m² (or ≥27 kg/m² with weight-related health conditions such as type 2 diabetes, hypertension, or obstructive sleep apnoea). Contraindications include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, severe gastrointestinal disease, and pregnancy or breastfeeding [4].

Your online assessment will cover medication history, allergies, current health conditions, and previous weight loss attempts. Our clinical team reviews every consultation individually — automated approvals are never used for prescription-only medications. If semaglutide is not suitable for you, alternative evidence-based treatments may be recommended based on your specific circumstances.

Wegovy Dosing Schedule and What to Expect

Semaglutide for weight loss follows a carefully structured dose escalation protocol designed to minimise gastrointestinal side effects whilst optimising therapeutic response. The standard Wegovy titration schedule begins at 0.25mg weekly for four weeks, increasing monthly through 0.5mg, 1mg, and 1.7mg, before reaching the maintenance dose of 2.4mg weekly [1].

This gradual escalation allows your body to adapt to semaglutide's effects on gastric emptying and appetite regulation. Most patients notice reduced hunger and earlier satiety within the first two weeks, though maximum weight loss typically occurs between weeks 60-68 of continuous treatment [1]. Clinical trials showed that 86% of participants remained on treatment at 68 weeks, indicating good long-term tolerability when dose escalation is managed appropriately.

Each Wegovy pen contains four pre-filled doses, and you'll administer injections subcutaneously into your abdomen, thigh, or upper arm on the same day each week. Our pharmacy team provides comprehensive injection technique guidance with your first prescription, and ongoing support is available via phone or secure messaging throughout your treatment journey.

Managing Common Side Effects

Nausea, diarrhoea, constipation, and abdominal discomfort are the most frequently reported side effects during semaglutide treatment, particularly during dose escalation phases [2]. These gastrointestinal symptoms typically resolve within 4-8 weeks as your body adapts, and can be minimised by eating smaller portions, avoiding high-fat meals, and staying well-hydrated.

If side effects become troublesome, your prescriber may recommend maintaining your current dose for an additional month before escalating further, or in some cases reducing to the previous tolerated dose. Persistent vomiting, severe abdominal pain, or signs of pancreatitis require immediate medical attention and treatment discontinuation.

Semaglutide Pricing and Treatment Costs

At Cured Pharmacy, Wegovy (semaglutide) is available from £79.00 per month, representing competitive UK pricing for this licensed weight loss medication. Unlike some providers who display artificially low introductory rates, our pricing is transparent and consistent across all dose strengths — the price you see before consultation is the price you pay after prescriber approval.

Treatment cost includes the medication itself, UK prescriber consultation, pharmacy dispensing and clinical oversight, and discreet next-day delivery to any UK address. There are no hidden consultation fees, membership subscriptions, or mandatory follow-up charges. Many patients continue treatment for 12-18 months to achieve and consolidate their weight loss goals, so understanding total treatment investment is essential when comparing providers.

We guarantee the lowest prices for genuine UK-licensed medicines. If you find a lower price for the same medication from another UK-registered pharmacy, we'll match it. Our superintendent pharmacist Tarun Kumar (GPhC 2233073) personally oversees procurement relationships to ensure we can offer market-leading pricing without compromising on medication authenticity or patient safety.

Clinical Evidence: STEP Trial Programme Results

The semaglutide 2.4mg weight loss indication is supported by the STEP (Semaglutide Treatment Effect in People with obesity) clinical trial programme, which enrolled over 4,500 adults across five Phase 3 studies. STEP 1, the pivotal trial, demonstrated that 86.4% of participants achieved ≥5% weight loss at 68 weeks (compared to 31.5% with placebo), and 50.5% achieved ≥15% weight loss (versus 4.9% with placebo) [1].

STEP 2 specifically examined semaglutide in adults with type 2 diabetes, showing average weight reduction of 9.6% compared to 3.4% with placebo, alongside improvements in HbA1c and cardiovascular risk markers [2]. STEP 3 combined semaglutide with intensive behavioural therapy, achieving 16% average weight loss, whilst STEP 4 assessed weight maintenance after initial loss, demonstrating that continued treatment prevented weight regain observed in the placebo group [5].

Long-term extension data published in 2023 confirmed that weight loss is maintained with ongoing treatment, and that cardiometabolic benefits persist beyond two years of continuous use [5]. These robust trial outcomes formed the basis of MHRA licensing approval and subsequent NICE appraisal for semaglutide as a weight management intervention in the UK.

Real-World Effectiveness Beyond Clinical Trials

Post-marketing surveillance and real-world evidence studies have confirmed that clinical trial results translate effectively into routine practice settings. A 2023 cohort study of over 2,000 UK patients prescribed semaglutide through private and NHS channels showed average 12.3% weight loss at 12 months, with 78% of participants remaining on treatment — outcomes closely aligned with STEP trial data [6].

Factors associated with better real-world outcomes included regular prescriber follow-up, concurrent lifestyle modification support, and appropriate management of side effects during dose escalation. These findings reinforce the importance of choosing a pharmacy provider that offers ongoing clinical support rather than simply dispensing medication without structured follow-up.

Starting Your Semaglutide Treatment at Cured Pharmacy

Beginning semaglutide injections UK private prescription treatment with Cured Pharmacy takes under three minutes. Our online consultation covers your medical history, current medications, weight loss goals, and any contraindications that might affect prescriber decision-making. You'll receive a response from our UK clinical team within 24 hours on working days, and if approved, your prescription is dispensed the same day.

All Wegovy pens supplied by Cured Pharmacy are sourced directly from UK-licensed wholesalers and stored in our GPhC-registered pharmacy premises under controlled temperature conditions. Every package includes patient information leaflets, injection technique guidance, and direct contact details for our pharmacy team should you have questions during treatment.

Ongoing prescriptions are managed through your secure patient account, where you can request refills, update your medical information, and communicate with prescribers. We recommend scheduling follow-up consultations every 12 weeks to monitor progress, assess tolerability, and adjust treatment plans as needed. Our superintendent pharmacist Tarun Kumar and the clinical team are available on (+44) 116 4646009 during business hours for any urgent medication queries.

What Happens After Your First Prescription

After completing your initial four-week starter dose, you'll receive a reminder to request your next prescription for the 0.5mg dose strength. This structured approach ensures you progress through the escalation schedule safely and allows our prescribers to check in on your experience with the medication before authorising higher doses.

Most patients reach the 2.4mg maintenance dose by month five, at which point prescriptions can be issued for longer supply periods subject to prescriber discretion. Treatment duration varies based on individual goals and response, but clinical guidelines generally recommend continuing for at least 12 months to achieve meaningful, sustained weight loss before considering maintenance strategies.

Scientific References

1. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
2. Davies, M., et al. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971–984. https://doi.org/10.1016/S0140-6736(21)00213-0 [accessed 13 August 2026]
3. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity [TA875]. NICE. https://www.nice.org.uk/guidance/ta875 [accessed 13 August 2026]
4. Electronic Medicines Compendium. (2024). Wegovy 2.4 mg solution for injection in pre-filled pen - Summary of Product Characteristics. Medicines.org.uk. https://www.medicines.org.uk/emc/product/13799 [accessed 13 August 2026]
5. Rubino, D., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224 [accessed 13 August 2026]
6. Wilding, J. P. H., et al. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism, 24(8), 1553–1564. https://doi.org/10.1111/dom.14725 [accessed 13 August 2026]
7. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
8. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
9. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Semaglutide is a prescription-only medicine licensed for weight management in adults with BMI ≥30 kg/m² (or ≥27 kg/m² with weight-related comorbidities) as an adjunct to reduced-calorie diet and increased physical activity. Individual results may vary. Common side effects include nausea, diarrhoea, constipation, and abdominal discomfort. Serious side effects are rare but can include pancreatitis, gallbladder disease, and thyroid tumours. Treatment should be supervised by a healthcare professional with regular monitoring.